Perspective Therapeutics FY2025 EPS Lifted by Wedbush

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Investment analysts at Wedbush increased their FY2025 EPS estimates for Perspective Therapeutics in a research note issued to investors on Tuesday, November 11th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($1.33) for the year, up from their previous estimate of ($1.34). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics’ Q4 2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($1.27) EPS.

A number of other equities analysts have also weighed in on CATX. BTIG Research began coverage on Perspective Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 3rd. Four investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $11.89.

Perspective Therapeutics Stock Down 4.0%

NYSEAMERICAN:CATX traded down $0.09 during trading hours on Thursday, reaching $2.04. 167,000 shares of the company traded hands, compared to its average volume of 1,008,623. The business’s 50-day moving average price is $3.30 and its two-hundred day moving average price is $3.32. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $10.06.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the period. Patient Square Capital LP purchased a new stake in shares of Perspective Therapeutics in the 3rd quarter worth approximately $1,198,000. Siligmueller & Norvid Wealth Advisors LLC purchased a new stake in shares of Perspective Therapeutics in the 3rd quarter worth approximately $565,000. Vanguard Group Inc. boosted its position in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Perspective Therapeutics in the third quarter valued at about $46,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.